Prescription Required
In stock
Manufacturer
ACCORD HEALTHCA
SKU
16729003001

methyldopa 250 mg tablet

Generic
$0.10 / tablet
$0.38 / tablet
$0.28 / tablet
+ -
1,000 tablets Available
Total Price:

Uses

Hypertension

Methyldopa is used alone or in combination with other classes of antihypertensive agents in the management of hypertension. Although other antihypertensive drug classes (angiotensin-converting enzyme [ACE] inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and thiazide diuretics) are preferred for the initial management of hypertension in adults, centrally acting agents such as methyldopa may be considered as add-on therapy if goal blood pressure cannot be achieved with the recommended drugs.

IV methyldopate hydrochloride may be used for the management of hypertension when parenteral hypotensive therapy is necessary.

Methyldopa generally is most effective when used with a diuretic. The use of a diuretic may prevent tolerance to methyldopa and permit reduction of methyldopa dosage. Diuretics may also prevent sodium retention and increased plasma volume that may occur after prolonged methyldopa therapy. (See Cautions: Cardiovascular Effects.) Methyldopa also has been used with other antihypertensive agents, permitting a reduction in the dosage of each drug and, in some patients, minimizing adverse effects while maintaining blood pressure control. (See Drug Interactions: Diuretics and Hypotensive Agents.) The possibility that geriatric patients may not tolerate the adverse cognitive effects of centrally acting hypotensive agents such as methyldopa should be considered. Methyldopa is generally considered to be safe for use in patients with renal failure.

Hypertension during Pregnancy

Methyldopa has been used effectively for the management of hypertension in pregnant women without apparent substantial adverse effects on the fetus.

The goal of antihypertensive treatment in pregnant women with hypertension is to minimize the acute complications of maternal hypertension while avoiding therapy that would compromise fetal well-being. Antihypertensive therapy is recommended in pregnant women with chronic hypertension who have persistent, severely elevated levels of blood pressure (e.g., systolic blood pressure of 160 mm Hg or higher or diastolic blood pressure of 105 mm Hg or higher); it is less clear whether antihypertensive therapy should be initiated in women with mild to moderate chronic hypertension. Although methyldopa has been used for many years in the management of hypertension in pregnant women and historically has been considered the initial agent of choice when antihypertensive therapy is necessary during pregnancy, the American College of Obstetricians and Gynecologists (ACOG) and other experts currently recommend use of one of several agents (labetalol, nifedipine, or methyldopa) when initiation of antihypertensive therapy is necessary in a pregnant woman. In women who are already receiving antihypertensive therapy prior to pregnancy, ACOG states there are insufficient data to make recommendations regarding the continuance or discontinuance of such therapy; treatment decisions should be individualized in these situations. Antihypertensive therapy can reduce the risk of severe hypertension but has not been shown to prevent the development of preeclampsia. Use of methyldopa in association with careful prenatal management during pregnancy appears to be safe for mother and fetus.(See Pregnancy under Cautions: Pregnancy, Fertility, and Lactation.)

Hypertensive Crises

IV methyldopate hydrochloride has been used for the management of hypertensive emergencies; however, because of the slow onset of action of this drug, other agents (e.g., labetalol, esmolol, fenoldopam, nicardipine, sodium nitroprusside) are preferred.

Pheochromocytoma

Methyldopa and methyldopate hydrochloride are not recommended for use in patients with pheochromocytoma.

Dosage and Administration

Administration

Methyldopa is administered orally; methyldopate hydrochloride is administered by IV infusion. IM or subcutaneous administration of methyldopate hydrochloride is not recommended because of unpredictable absorption.

Methyldopate hydrochloride IV infusions are prepared by adding the required dose of the drug to 100 mL of 5% dextrose injection. Alternatively, the required dose may be administered in 5% dextrose injection in a concentration of 100 mg/10 mL. The IV infusion should be administered slowly over a period of 30-60 minutes. ADD-Vantage vials labeled as containing 50 mg/mL of methyldopate hydrochloride should be diluted and administered according to the manufacturer's directions. Vials containing solutions of methyldopate hydrochloride for injection and reconstituted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosage

Dosage of methyldopa must be adjusted according to the patient's blood pressure response and tolerance. Adverse effects such as drowsiness may be minimized by starting dosage increases in the evening or by giving a larger dose at bedtime than in the morning. Geriatric patients may respond to smaller doses of methyldopa.

Hypertension

Monotherapy

The usual initial adult oral dosage of methyldopa is 250 mg 2 or 3 times daily for 2 days. Dosage may then be increased or decreased at intervals of at least 2 days until an adequate response is achieved. The usual maintenance dosage of methyldopa recommended by the manufacturers is 500 mg to 2 g daily given in 2-4 divided doses; dosages exceeding 3 g daily are not recommended by the manufacturers, although some patients have required such dosages. Some experts recommend a lower usual dosage range of 125-500 mg twice daily; the rationale for this reduced dosage is that it usually is preferable to add another antihypertensive agent to the regimen than to increase maximum methyldopa dosage beyond 1 g daily because of poor patient tolerance of increasing dosages of the drug. In some patients, administration of methyldopa as a single daily dose at bedtime may provide adequate blood pressure control during maintenance therapy.

In children, the usual initial oral dosage of methyldopa is 10 mg/kg daily or 300 mg/m daily, given in 2-4 divided doses. Dosage is adjusted at intervals of at least 2 days until an adequate response is achieved. The maximum oral dosage in children is 65 mg/kg daily, 2 g/m daily, or 3 g daily, whichever is least.

Combination Oral Therapy

When methyldopa is administered with other hypotensive drugs, the initial adult oral dosage should not exceed 500 mg daily in divided doses. Tolerance to methyldopa may occur between the second and third month of therapy and an increase in dosage or concomitant use of a thiazide diuretic may be required to restore effective blood pressure control.

When combination therapy is required, commercially available products containing methyldopa in fixed combination with a thiazide diuretic should not be used initially. Dosage should first be adjusted by administering each drug separately. If it is determined that the optimum maintenance dosage corresponds to the ratio in a commercially available fixed-combination preparation, such a product may be used. However, whenever dosage adjustment is necessary, the drugs should be administered separately. If combination therapy is initiated with the fixed-combination preparation, the initial dosage is 250 mg of methyldopa and 15 mg of hydrochlorothiazide given 2 or 3 times daily, or alternatively, 250 mg of methyldopa and 25 mg of hydrochlorothiazide given twice daily. Patients requiring higher dosages of the fixed-combination preparation may receive once-daily administration of 500 mg of methyldopa and 30 mg of hydrochlorothiazide, or alternatively, 500 mg of methyldopa and 50 mg of hydrochlorothiazide. When administered with another antihypertensive agent, dosages of hydrochlorothiazide should not exceed 50 mg daily.

Blood Pressure Monitoring and Treatment Goals

Careful monitoring of blood pressure during initial titration or subsequent upward adjustment in dosage of methyldopa is recommended.

The goal of hypertension management and prevention is to achieve and maintain optimal control of blood pressure; specific target levels of blood pressure should be individualized based on consideration of multiple factors, including patient age and comorbidities, and the currently available evidence from clinical studies.

IV Dosage

The usual adult IV dosage of methyldopate hydrochloride is 250-500 mg every 6 hours as required; the maximum dosage is 1 g every 6 hours. The usual pediatric IV dosage of methyldopate hydrochloride is 20-40 mg/kg per 24 hours or 0.6-1.2 g/m per 24 hours, administered in equally divided doses at 6-hour intervals. The maximum IV dosage in children is 65 mg/kg daily, 2 g/m daily, or 3 g daily, whichever is least. When blood pressure is controlled, oral therapy should be substituted at the same dosage.

Dosage in Renal Impairment

Patients with impaired renal function may respond to smaller doses of methyldopa.

Cautions

Nervous System Effects

The most common adverse effect of methyldopa is drowsiness which occurs within the first 48-72 hours of therapy and may disappear with continued administration of the drug. Sedation commonly recurs when dosage is increased. A persistent decrease in mental acuity, including impaired ability to concentrate, lapses of memory, and difficulty in performing simple calculations, may occur and usually necessitates withdrawal of the drug. Other adverse nervous system effects which occur early in therapy include vertigo, headache, asthenia, and weakness.

Adverse CNS effects, which are less common than sedation and decreased mental acuity, include paresthesia, parkinsonism, and Bell's palsy. Involuntary choreoathetotic movements have been reported rarely in patients with severe bilateral cerebrovascular disease and are an indication for discontinuance of the drug. Psychic disturbances including nightmares and reversible mild psychoses or mental depression have also occurred.

Cardiovascular Effects

Orthostatic hypotension with attendant dizziness, lightheadedness, and symptoms of cerebrovascular insufficiency may occur during methyldopa therapy and is an indication for dosage reduction. Orthostatic hypotension may be less pronounced with methyldopa than with guanethidine or ganglionic blocking agents but may be more severe than with reserpine, clonidine, hydralazine, propranolol, or thiazides. Syncope in older patients may be related to an increased sensitivity to methyldopa and advanced arteriosclerotic vascular disease and may be avoided by using lower dosages.

Bradycardia may occur occasionally in patients receiving methyldopa. Aggravation of angina pectoris, congestive heart failure, and prolonged carotid sinus hypersensitivity have also been reported. Following IV administration of methyldopate hydrochloride, a paradoxical pressor response has been reported. Rebound hypertension has occurred rarely following abrupt withdrawal of oral methyldopa.

Sodium retention resulting in edema and weight gain has been reported in patients receiving methyldopa and can usually be controlled by concomitant administration of a thiazide diuretic. If edema cannot be controlled by diuretics and becomes progressive or leads to congestive heart failure, methyldopa should be discontinued.

Hematologic Effects

Positive direct antiglobulin (Coombs') test results have been reported in about 10-20% of patients receiving methyldopa, usually after 6-12 months of therapy. This phenomenon is dose related, with the lowest incidence in patients receiving 1 g or less of methyldopa daily. In most patients, a positive Coombs' test associated with methyldopa therapy is not clinically important. Reversal of the positive Coombs' test occurs within weeks to months after discontinuance of the drug and usually becomes negative within 6 months. Hemolytic anemia has only rarely occurred, although 2 deaths have been reported in patients with methyldopa-induced hemolytic anemia. If anemia or a positive Coombs' test occurs, appropriate laboratory studies should be performed to determine if hemolysis is present; if there is evidence of hemolytic anemia, the drug should be discontinued. (See Cautions: Precautions and Contraindications.) Discontinuance of the drug alone or initiation of corticosteroid therapy has produced remission of methyldopa-induced hemolytic anemia.

Reversible leukopenia (primarily granulocytopenia) and immune thrombocytopenia have occurred rarely during methyldopa therapy. Methyldopa may cause hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency. Positive lupus and rheumatoid factor tests have been reported to result from methyldopa therapy.

Sensitivity Reactions and Hepatic Effects

A major toxic effect of methyldopa is drug-induced fever, usually occurring within 3 weeks after initiation of treatment. In some patients, fever has been associated with an influenza-like illness (i.e., generalized malaise and anorexia). Fever may also be associated with eosinophilia or abnormal liver function test results, such as increased serum concentrations of alkaline phosphatase, aminotransferases, and bilirubin and abnormal prothrombin time. Rarely, reversible jaundice, with or without fever, has been reported, usually within the first 2-3 months of therapy, but occasionally after long-term therapy. In some patients, laboratory tests and liver biopsies have been consistent with cholestasis, hepatitis, hepatocellular injury, or cirrhosis. Hepatic necrosis, which may be fatal, is rare. Hepatic changes may represent hypersensitivity reactions. Methyldopa therapy should be stopped if unexplained fever or jaundice occurs or if liver function test results are abnormal. (See Cautions: Precautions and Contraindications.) If methyldopa is the causative agent, temperature and liver function generally return to normal within a few months after the drug is discontinued.

Eosinophilia, myocarditis, pericarditis, vasculitis, and lupus-like syndrome have been reported as hypersensitivity reactions to methyldopa. Three cases of sialadenitis accompanied by fever have been reported in patients receiving methyldopa; 2 of these patients also had nasal congestion and pharyngitis.

GI Effects

Adverse GI effects including nausea, vomiting, diarrhea, dry mouth, distention, constipation, flatus, and sore or ''black'' tongue have been reported during methyldopa therapy. Pancreatitis has also occurred. At least one case of colitis associated with hepatitis has been reported.

Dermatologic Effects

Adverse dermatologic effects associated with methyldopa include rash, urticaria, eczema, ulceration of the soles of the feet, hyperkeratosis, and lichenoid eruptions. At least one case of granulomatous nodular skin lesions associated with fever, arthralgia, and myalgia has been reported. Tongue ulcerations with features of lichen planus have occurred.

Other Adverse Effects

Nasal congestion occurs commonly in patients receiving methyldopa. Decreased libido and impotence frequently occur in males during therapy with the drug. Breast enlargement, gynecomastia, hyperprolactinemia, lactation, and amenorrhea have been reported rarely in patients receiving the drug. At least one case of retroperitoneal fibrosis may have been caused by methyldopa. Blurred vision, nocturia, and increased BUN and serum amylase concentrations have been reported.

Precautions and Contraindications

When methyldopa is used as a fixed-combination preparation that includes hydrochlorothiazide, the cautions, precautions, and contraindications associated with thiazide diuretics must be considered in addition to those associated with methyldopa.

When methyldopa therapy is started, hemoglobin, hematocrit, or a red blood cell count should be done and periodic blood counts should be performed during therapy to detect hemolytic anemia. Hepatic function should be determined periodically, especially during the first 6-12 weeks of therapy or whenever unexplained fever occurs. If the need for a blood transfusion occurs in patients receiving methyldopa, prior knowledge of a positive Coombs' reaction will aid in the evaluation of a cross match; therefore, a direct Coombs' test before methyldopa therapy and after 6 and 12 months of therapy may be useful. A positive direct Coombs' test prior to methyldopa therapy is not in itself a contraindication to use of the drug. Patients receiving methyldopa who need a transfusion should have both a direct and an indirect Coombs' test performed. In the absence of hemolytic anemia, usually only the direct Coombs' test will be positive; a positive direct Coombs' test alone will not interfere with typing or cross matching. If both the indirect and direct Coombs' tests are positive, problems with major cross matching may occur and the assistance of an expert in this area may be required.

If anemia or a positive Coombs' test occur during methyldopa therapy, appropriate laboratory studies should be performed to determine if hemolysis is present; if there is evidence of hemolytic anemia, the drug should be discontinued. The anemia usually remits promptly; if not, corticosteroids may be given and other causes of anemia should be considered and investigated. If the hemolytic anemia is related to methyldopa, therapy with the drug should not be reinstituted. Similarly, if unexplained fever, abnormal liver function test results, or jaundice occurs during methyldopa therapy, the drug should be discontinued; if these effects are caused by the drug, methyldopa therapy should not be reinstituted.

Patients who are receiving methyldopa and who undergo dialysis may occasionally become hypertensive after the dialysis, since the drug is dialyzable.

Patients should be warned that methyldopa may impair their ability to perform activities requiring mental alertness or physical coordination (e.g., operating machinery, driving a motor vehicle). Rarely, involuntary choreoathetotic movements have occurred during methyldopa therapy in patients with severe bilateral cerebrovascular disease; if these effects occur, the drug should be discontinued.

Commercially available formulations of methyldopate hydrochloride may contain sulfites, which can cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in certain susceptible individuals. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low; such sensitivity appears to occur more frequently in asthmatic than in nonasthmatic individuals.

Methyldopa should be used with caution in patients with a history of previous liver disease or dysfunction and is not recommended for use in patients with pheochromocytoma. Methyldopa is contraindicated in patients with active hepatic disease, such as acute hepatitis and active cirrhosis, and in patients in whom previous methyldopa therapy was associated with liver abnormalities or direct Coombs' positive hemolytic anemia. Methyldopa is contraindicated in patients receiving monoamine oxidase (MAO) inhibitors. Methyldopa is also contraindicated in patients who are hypersensitive to the drug or any ingredient in its formulation.

Pediatric Precautions

There have been no well-controlled studies to date using oral or IV preparations of methyldopa in pediatric patients. Dosage recommendations in children are based on published literature concerning use of methyldopa in hypertensive pediatric patients. The manufacturer states that safety and efficacy of preparations containing methyldopa in fixed combination with hydrochlorothiazide in pediatric patients have not been established. For information on overall principles and expert recommendations for treatment of hypertension in pediatric patients,

Mutagenicity and Carcinogenicity

Methyldopa was not mutagenic in the Ames test and did not increase chromosomal aberration or sister chromatid exchanges in Chinese hamster ovary cells; the in vitro studies were performed both with and without metabolic activation.

In a 2-year study, there was no evidence of tumorigenic effect when methyldopa was given to mice at dosages up to 1800 mg/kg daily (30 or 2.5 times the maximum human daily dosage when compared on the basis of body weight or body surface area, respectively) or to rats at dosages up to 240 mg/kg daily (4 or 0.6 times the maximum human daily dosage when compared on the basis of the body weight or body surface area, respectively).

Pregnancy, Fertility, and Lactation

Pregnancy

Reproduction studies in mice, rabbits, and rats using oral methyldopa in dosages of 1000, 200, and 100 mg/kg, respectively, have not revealed evidence of harm to the fetus. These dosages are 16.6, 3.3, and 1.7 times, respectively, the maximum daily human dosage when compared on the basis of body weight and 1.4, 1.1, and 0.2 times, respectively, the maximum daily human dosage when compared on the basis of body surface area.

Methyldopa has been used for many years in the management of hypertension in pregnant women, and the drug is generally considered safe for mother and fetus when used in association with careful prenatal management. Uteroplacental blood flow and fetal hemodynamics have been reported to be stable during therapy with the drug. Although no teratogenic effects have been reported, the possibility that methyldopa may cause fetal injury (e.g., secondary to reduced placental blood flow or fetotoxicity) cannot be excluded.

In neonates born to women treated with methyldopa, systolic blood pressure may be decreased during the first 2-3 days after delivery; in some neonates, tremors have also been reported. Studies to date, including a long-term follow-up study, of children born to women who received methyldopa during pregnancy have not revealed evidence of substantial adverse effects of the drug on the offspring; however, in the longest follow-up study, treatment with methyldopa was associated with a smaller head circumference (without an apparent effect on intelligence quotient) in male offspring of those women whose therapy was initiated between 16 and 20 weeks' gestation. At 4 years of age, the developmental delay commonly seen in children born to hypertensive mothers was less evident in those whose mothers received methyldopa during pregnancy than in those whose mothers were untreated. Children born to mothers receiving methyldopa scored consistently higher on indices of intellectual and motor development than children born to untreated hypertensive mothers; however, these differences were not apparent by 7.5 years of age.

Methyldopa should be used during pregnancy only when clearly needed. In addition, excessive reduction in blood pressure should be avoided, and a conservative approach to treatment generally should be followed.(See Hypertension during Pregnancy under Uses: Hypertension.)

Fertility

Reproduction studies in male and female rats using methyldopa dosages of 100 mg/kg daily (1.7 times or 0.2 times the maximum recommended daily human dosage when compared on the basis of body weight or body surface area, respectively) have not revealed evidence of impaired fertility. However, in male rats given 200 mg/kg daily (3.3 or 0.5 times the maximum daily human dosage when compared on the basis of body weight or body surface area, respectively) or 400 mg/kg daily (6.7 or 1 times the maximum daily human dosage on the basis of body weight or body surface area, respectively), there were decreases in sperm count, sperm motility, number of late spermatids, and male fertility index.

Lactation

Since methyldopa is distributed into milk, the drug should be used with caution in nursing women; the possibility of adverse effects on a nursing infant cannot be excluded. The extent to which methyldopa distributes into milk has not been clearly established, but the amount of drug a nursing infant would ingest is believed to be too small to be clinically important; however, if a woman receiving methyldopa breastfeeds, the infant (particularly if preterm) should be monitored for potential systemic effects of the drug (e.g., decreased respiration, blood pressure, or alertness).

Drug Interactions

Diuretics and Hypotensive Agents

When methyldopa is administered with diuretics or other hypotensive agents, the hypotensive effect of methyldopa may be increased. This effect is usually used to therapeutic advantage, but careful adjustment of dosage is necessary when these drugs are used concomitantly.

Psychotherapeutic Agents

Patients receiving methyldopa and phenothiazines or tricyclic antidepressants should be monitored for a possible reduction in hypotensive effect. Although methyldopa has been used with haloperidol and chlorpromazine to treat patients with schizophrenic disorder, nonschizophrenic patients have developed symptoms such as psychomotor retardation, memory impairment, and inability to concentrate when haloperidol was added to methyldopa therapy; these symptoms disappeared when haloperidol was discontinued.

Methyldopa and monoamine oxidase inhibitors are not to be used concomitantly.

Patients receiving lithium carbonate have developed signs and symptoms of lithium toxicity when methyldopa was added to their therapy. Therefore, patients receiving the drugs concomitantly should be monitored for lithium toxicity and therapy with the drugs adjusted accordingly.

Levodopa

Methyldopa should be used with caution in patients receiving levodopa, since an additive hypotensive effect may occur. In addition, methyldopa can cause toxic CNS effects such as psychosis if administered concomitantly with levodopa.

Oral Iron Preparations

Results of one cross-over study in healthy adults indicate that concomitant administration of a single oral dose of ferrous sulfate (325 mg) or ferrous gluconate (600 mg) can decrease oral absorption of methyldopa (500 mg) by 61-73%. In addition, concomitant administration of these oral iron preparations appears to affect metabolism of methyldopa since there was a 79-88% decrease in urinary excretion of free methyldopa and an increase in urinary excretion of the sulfate conjugate of the drug. When oral ferrous sulfate therapy (325 mg every 8 hours) was initiated in a group of hypertensive patients receiving chronic methyldopa therapy (250 mg 1-3 times daily or 500 mg 3 times daily), there was an increase in blood pressure during concomitant therapy and a decrease in blood pressure when the oral iron preparation was discontinued. Therefore, at least one manufacturer states that concomitant administration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.

Other Drugs

Patients receiving methyldopa may require reduced doses of general anesthetics; if hypotension occurs during anesthesia, the manufacturers state that vasopressor drugs are usually effective. In patients receiving methyldopa, norepinephrine should be administered cautiously, beginning with small doses, since the magnitude and duration of the pressor response to norepinephrine may be enhanced. Theoretically, the effect of ephedrine may be reduced in methyldopa-treated patients, since methyldopa reduces the quantity of norepinephrine in sympathetic nerve endings and ephedrine activity is due to an indirect effect resulting in release of norepinephrine. Clinically, methyldopa treatment has decreased the mydriasis produced by topical ephedrine. Theoretically, amphetamines may increase sympathetic activity and result in a decrease in the hypotensive effect of methyldopa.

Pharmacokinetics

Absorption

Methyldopa is partially absorbed from the GI tract. The degree of absorption varies among individuals and in the same patient from day to day, but generally about 50% of an oral dose is absorbed. Plasma concentrations of methyldopa generally do not correlate with therapeutic effect. Following oral administration of methyldopa, peak plasma concentrations of the drug occur in approximately 3-6 hours. Mean plasma concentrations of the drug 3 hours after a 750-mg dose are approximately 3.4 mcg/mL. The maximum decrease in blood pressure occurs in 4-6 hours after oral administration of methyldopa. Once an adequate oral dosage level is attained, optimum blood pressure response occurs in 12-24 hours in most patients. After withdrawal of the drug, blood pressure usually returns to pretreatment levels within 24-48 hours.

Methyldopate hydrochloride is hydrolyzed in the body to form methyldopa; hydrolysis is somewhat delayed. The mean plasma concentration of methyldopa 60 minutes after IV administration of 250 mg of methyldopate hydrochloride is approximately 1.7 mcg/mL. After IV administration of methyldopate hydrochloride, the hypotensive effect begins in 4-6 hours and lasts 10-16 hours.

Distribution

Methyldopa and its metabolites are weakly bound to plasma proteins.

Animal studies indicate that the drug crosses the blood-brain barrier. Methyldopa crosses the placenta in humans. Methyldopa is distributed into milk; peak milk concentrations of free methyldopa are approximately 20-35% of those in maternal plasma following an individual dose during continuous therapy. The extent of distribution of methyldopa into milk has not been clearly determined, but it is estimated that about 0.02% of a daily maternal dose of 1 g would be ingested by a nursing infant and that this amount is probably not clinically important.

Elimination

Plasma concentrations of methyldopa decline in a biphasic manner; in patients with normal renal function, 95% of the drug is eliminated during the initial phase with a plasma half-life of 1.8 hours; the second phase is much slower. Renal clearance of the drug is decreased in patients with renal insufficiency. In patients with severely impaired renal function, about 50% of the drug is excreted during the initial phase with a half-life of 3.6 hours.

Methyldopa is extensively metabolized mainly to the conjugate, methyldopa mono-O-sulfate, probably in the GI tract and the liver. Conjugation occurs to a greater extent when the drug is given orally than when it is given IV. The sulfate conjugate of methyldopa may be therapeutically active. There is wide interindividual difference in the ratio of free to conjugated methyldopa in the plasma. The rate of conjugation of methyldopa is decreased in patients with renal insufficiency. Unchanged methyldopa and its conjugates are the major constituents found in plasma and urine, but small amounts of decarboxylated derivatives have also been identified.

Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. Delayed excretion and accumulation of this metabolite occur in patients with renal insufficiency and may cause an increased hypotensive effect during methyldopa therapy. Unabsorbed methyldopa is excreted in the feces unchanged. Methyldopa is removed by hemodialysis and peritoneal dialysis.

Write Your Own Review
You're reviewing:METHYLDOPA 250 MG TABLET
Your Rating